Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine versus placebo for depression, withdrawal symptoms, and craving in methamphetamine dependence
IRCT20160717028967N7Phase 2Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of duloxetine in methamphetamine use disorder (MUD) and major depressive disorder (MDD) (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoints: Depression, Withdrawal signs and 1 more. Started Jul 2018; status: completed.
02
Drugs
duloxetine
03
Conditions
methamphetamine use disorder (MUD)major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20160717028967N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160717028967N7.